Suggested Remit: To appraise the clinical and cost effectiveness of ibrutinib with venetoclax within its marketing authorisation for untreated chronic lymphocytic leukaemia.
Status Awaiting development
Process STA 2018
ID number 3860

Provisional Schedule

Expected publication 01 March 2023

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
28 September 2021 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-April 2022.
29 July 2021 - 25 August 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: Cancer
26 February 2021 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-October 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2022.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance